Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,260.92
(
-1.01%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RockRat post# 104107

Monday, 09/13/2010 5:37:00 PM

Monday, September 13, 2010 5:37:00 PM

Post# of 257580

We're definitely talking about enzymatic cleavage in this instance. I'm sure Momenta uses both chemical and enzymatic cleavage.

For Lovenox, specifically, MNTA uses only chemical cleavage, and Wheeler himself has confirmed this. For various other compounds MNTA may be developing, we may presume that both chemical and enzymatic cleavage come into play.

The patent awarded today has broader applicability than just Lovenox and heparin-based drugs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today